In the News

Share

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1729 News Items found
Sohrab Shah
Cancer-Like Mutations in Healthy Cells Point to Origins of Breast Cancer

A multi-institution team co-led by MSK researchers has pinpointed what could be the early genetic origins of breast cancer.
Michael Rosensweig with dog
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients one year and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called a KMT2A translocation.
Q&A
Hematologic oncologist Eytan Stein and nurse practitioner Coleen Ranaghan consult with a patient.
How Acute Myeloid Leukemia Is Treated at MSK: An Interview With Eytan Stein

In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.
Ask the Expert
Thoracic medical oncologist Dr. Mark Awad
New Lung Cancer Treatments Aim to Reduce Deaths in 2025 and Beyond

Learn about the latest advances in lung cancer treatment at MSK.
Dr. Michael Tuttle consults with a patient in an exam room
Why Active Surveillance Is a Good Option for Many Patients With Papillary Thyroid Cancer

Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.
a lab coat hangs in an MSK lab
MSK Research Highlights, November 6, 2024

New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Dr. Craig Thompson in his lab at the Sloan Kettering Institute
New MSK Research Reveals How Mitochondria Function Under Stress Like Cancer

Mitochondria provide both the energy cells need to survive and the building blocks they need to grow and divide. Researchers at the Sloan Kettering Institute reveal for the first time how mitochondria choose between these opposing paths — and what implications it may have for cancer.
John Petrini
Ancient Immune Defense System Plays an Unexpected Role in Cancer, MSK Researchers Find

Along with defending against pathogens, the body’s innate immune system helps to protect the stability of our genomes in unexpected ways — ways that have important implications for the development of cancer, researchers at MSK are discovering.
Nat, Alex, and Michael Wolff and Polly Draper
Fixing One Wrong Note: How MSK Precision Diagnostics Saved a Musician With a Rare Cancer

Learn how molecular testing and an experimental targeted therapy cured jazz musician Michael Wolff, who had the rare cancer histiocytic sarcoma.
MSK's Mark Awad, MD, PhD, is seen smiling.
Questions to Ask If You've Been Diagnosed With Lung Cancer

Learn about the questions to ask a lung cancer doctor after being diagnosed, from an MSK specialist who has successfully treated many people for lung cancer.